Skip to main content

Table 4 Clinical and/or radiographic progression of cancer during COVID-19 disease

From: Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies

Number of patients

10

Age (years), mean(range)

77.4 (39–81)

Gender

 Male

4(40)

 Female

6 (60)

Cancer Stage (UICC, 8th ed.), N (%)

 I

1 (10)

 II

0 (0)

 III

2 (20)

 IV

7 (70)

Histology, N (%)

 Renal cell carcinoma

4 (40)

 Prostate cancer

4 (40)

 Urothelial cancer

2 (20)

Course of COVID-19, N (%):

 Mild

0 (0)

 Mechanical ventilation

2 (20)

 Noncritical care hospitalization

4 (40)

 Critical care hospitalization (oxygen support)

4 (40)

Duration of COVID-19, median (days)

28.8

Death as a COVID-19 disease outcome, N (%)

4 (40)